Cathie's Ark LogoCathie's Ark
BEGIN TYPING TO SEARCH BY TICKER
CRISPR Therapeutics AG Logo

ARKK Holdings of CRISPR Therapeutics (CRSP) - Updated Daily

Date
Direction
Shares
Fund Weight
Fund
August 8, 2022
SELL8.727k0.0071%ARKK
August 5, 2022
SELL365.645k0.2851%ARKK
August 4, 2022
SELL70.723k0.0556%ARKK
August 3, 2022
SELL13.479k0.0112%ARKK
July 28, 2022
SELL32.936k0.0263%ARKK

Key Statistics

DateAugust 08, 2022Revenue
Expected$2.06m
Actual$158.00k
EPS
Expected-$2.23
Actual-$2.40
🕵🏼Found In🏷Last Price
ARKGARKK$75.13
⚖️Weighting🧢Market Cap
4.84%$5.86b
🏋🏿‍♂️Weight Rank In ARKK🧮Price to Sales
6395.44
🏋️‍♀️Weight Rank Across All Funds🌏Country
8🇨🇭Switzerland
💳ARK Estimated Cost Average🎫ARK Ownership Percent
$62.327.98%
Description
CRISPR Therapeutics is a leading gene editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases. To accelerate and expand its efforts, CRISPR Therapeutics has established strategic collaborations with leading companies including Bayer, Vertex Pharmaceuticals and ViaCyte, Inc.CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Cambridge, Massachusetts, and business offices in San Francisco, California and London, United Kingdom.
Website
crisprtx.com